Tomahawk, WI 3/21/2012 (StreetBeat) – Cannabis Science, Inc. (OTCBB:CBIS), a pioneering US biotech company developing pharmaceutical cannabis products, today announced, in a press release, its acquisition of The Kaneabis Brand through its parent company Cannabis Consulting Inc. Traders took note of this news and ran with it apparently with the boom in volume. As I write, shares of CBIS were up slightly at $0.09 per share on heavy volume of nearly 10 million shares.Cannabis Science also announced that Robert Kane has been promoted to the position of Vice President of Investor Relations, Mr. Robert Kane is in the process of relocating to Colorado Springs to help facilitate opening up the new Cannabis Science headquarters in Colorado Springs, Colorado.
Cannabis Science embraces Mr. Kane and his Kaneabis Brand. Each one of Mr. Kane's endeavors falls directly in line with Cannabis Science’s mission to establish the Medical Cannabis Industry as a viable pharmaceutical/nutraceutical business model and investment alternative for all investors.
For over a decade Robert J. Kane worked for Stifel Nicolaus (NYSE: SF) as a registered representative. Recognizing the Medical Cannabis Industry’s opportunity Mr. Kane left Stifel Nicolaus and began consulting Medical Cannabis Industry leaders mostly with business plans to support investment in the industry, and the Kaneabis brand was born.
Dr. Robert Melamede Ph.D., Cannabis Science President & CEO, stated, “For the last 6 months we have been working with Mr. Kane on a consulting basis and have been extremely pleased with his work ethic, expertise, and dedication to promoting the global 'cannabis awakening'. We have received a lot of positive feedback from shareholders, and we believe bringing Mr. Kane and his resources exclusively into the Cannabis Science business model is a good decision. It will better serve the needs of our shareholders and add additional revenue to our bottom line through the expanded line of services that we can now offer. These revenues, along with revenues generated from our other profit centers, should improve our balance sheet and give us access to the additional capital required to complete the FDA approval process.”
StreetBeat Disclaimer
No comments:
Post a Comment